FindTrial
Sign In

c-Cbl inhibits tumor angiogenesis by promoting METTL3 ubiquitination and pericytes apoptosis in melanoma

c-Cbl inhibits tumor angiogenesis by promoting METTL3 ubiquitination and pericytes apoptosis in melanoma

Status
Active, not recruiting
Phases
Unknown
Study type
Observational
Source
ChiCTR
Registry ID
ChiCTR2500112645
Enrollment
Unknown
Registered
2025-11-18
Start date
2025-12-01
Completion date
Unknown
Last updated
2025-11-24

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

malignant melanoma

Interventions

Non-Responders group:None
Responders group:None

Sponsors

The First Affiliated Hospital of Chongqing Medical University
Lead Sponsor

Eligibility

Sex/Gender
All

Inclusion criteria

Inclusion criteria: 1.Pathologically confirmed as melanoma; 2.No prior antitumor therapy had been administered before the diagnosis was confirmed.

Exclusion criteria

Exclusion criteria: 1.under the age of eighteen; 2.Presence of concurrent other malignancies at melanoma diagnosis, or history of other malignancies within the past 2 years;

Design outcomes

Primary

MeasureTime frame
Therapy response;—

Countries

China

Contacts

Public ContactShen Chengcheg

The First Affiliated Hospital of Chongqing Medical University

shencc@hospital.cqmu.edu.cn+86 15923503285

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Feb 4, 2026